NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer.
暂无分享,去创建一个
J. Garcia-conde | J. Baselga | F. Rojo | J. Albanell | A. Lluch | M. Molina | G. Clinton | R. Sáez | E. Ramsey | E. Keenan | A. Evans | M. Garcia-Barchino | R. Sáez
[1] K. Hagino-Yamagishi,et al. [Oncogene]. , 2019, Gan to kagaku ryoho. Cancer & chemotherapy.
[2] H. Moch,et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. , 2001, Journal of the National Cancer Institute.
[3] J. Baselga,et al. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. , 2001, Cancer research.
[4] C. Benz,et al. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] S. Wingren,et al. C-erbB-2 overexpression and survival in early onset breast cancer , 2000, Breast Cancer Research and Treatment.
[6] S. Edge,et al. Prognostic factors in breast cancer , 2005 .
[7] J. Ross,et al. Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in situ hybridization in breast cancer. , 1999, American journal of clinical pathology.
[8] H. Höfler,et al. Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up , 1999, British Journal of Cancer.
[9] J. Doherty,et al. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. , 1998, Cancer research.
[10] D Tripathy,et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] K Vajda,et al. [Prognostic factors in breast cancer]. , 1998, Orvosi hetilap.
[12] M. Silverstein,et al. Predictors of axillary lymph node metastases in patients with T1 breast carcinoma , 1997, Cancer.
[13] T. Fehm,et al. The Prognostic Significance of c-erbB-2 Serum Protein in Metastatic Breast Cancer , 1997, Oncology.
[14] G. Steger,et al. Soluble HER‐2/neu neutralizes biologic effects of anti‐HER‐2/neu antibody on breast cancer cells in vitro , 1997, International journal of cancer.
[15] G. Carpenter,et al. Constitutive Proteolysis of the ErbB-4 Receptor Tyrosine Kinase by a Unique, Sequential Mechanism , 1997, The Journal of cell biology.
[16] D. Slamon,et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] R. Gelman,et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] A. Ruíz,et al. Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status. , 1997, Clinica chimica acta; international journal of clinical chemistry.
[19] R. Molina,et al. Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3. , 1996, British Journal of Cancer.
[20] L. Stitt,et al. The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer. , 1996, Human pathology.
[21] R. B. Montgomery,et al. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. , 1996, Oncogene.
[22] M. Beckmann,et al. Expression analyses of epidermal growth factor receptor and HER-2/neu: no advantage of prediction of recurrence or survival in breast cancer patients. , 1996, Oncology.
[23] J. Biegel,et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. , 1995, Cancer research.
[24] P. Brandt-Rauf,et al. The c-erbB transmembrane growth factor receptors as serum biomarkers in human cancer studies. , 1995, Mutation research.
[25] A. Redkar,et al. Prognosis of breast cancer: Evidence for interaction between c‐erbB‐2 overexpression and number of involved axillary lymph nodes , 1995, Journal of surgical oncology.
[26] A. Scorilas,et al. c-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer patients. , 1995, Anticancer research.
[27] V. Chinchilli,et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] L. Seymour,et al. Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. , 1994, British journal of cancer.
[29] B. Têtu,et al. Prognostic significance of HER‐2/neu oncoprotein expression in node‐positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy , 1994, Cancer.
[30] G. Rodrigues,et al. Oncogenic activation of tyrosine kinases. , 1994, Current opinion in genetics & development.
[31] S. Ménard,et al. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. , 1993, Oncogene.
[32] L. Presta,et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[33] W. Carney,et al. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. , 1991, The Journal of biological chemistry.
[34] R. Fourney,et al. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. , 1991, Cancer research.
[35] G. Clinton,et al. Insulin and epidermal growth factor stimulate phosphorylation of p185HER-2 in the breast carcinoma cell line, BT474 , 1990, Molecular and Cellular Endocrinology.
[36] A. Ullrich,et al. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. , 1990, Cancer research.
[37] W. McGuire,et al. HER-2/neu oncogene protein and prognosis in breast cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] S. Aaronson,et al. Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene , 1988, Molecular and cellular biology.
[39] C R King,et al. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.
[40] I. Henderson,et al. The relationship between prognostic and predictive factors in the management of breast cancer , 2004, Breast Cancer Research and Treatment.
[41] Y. Yarden,et al. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. , 2000, Advances in cancer research.
[42] B. Lloveras,et al. Circulating HER 2 Extracellular Domain and Resistance to Chemotherapy in Advanced Breast Cancer 1 , 2000 .
[43] P. Ravdin. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer , 1999 .
[44] T. Singleton,et al. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. , 1992, Pathology annual.
[45] G. Clinton,et al. A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells. , 1991, Oncogene.
[46] C R King,et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.